Nagy Nikoletta, Dubois Anna, Szell Marta, Rajan Neil
Department of Medical Genetics, University of Szeged, Szeged, Hungary.
Dermatological Research Group of the Eotvos Lorand Research Network, University of Szeged, Szeged, Hungary.
Appl Clin Genet. 2021 Oct 29;14:427-444. doi: 10.2147/TACG.S288274. eCollection 2021.
CYLD cutaneous syndrome (CCS) is an inclusive label for the inherited skin adnexal tumour syndromes Brooke-Spiegler Syndrome (BSS-OMIM 605041), familial cylindromatosis (FC - OMIM 132700) and multiple familial trichoepitheliomas (MFT-OMIM 601606). All three syndromes arise due to germline pathogenic variants in , a tumour suppressor gene (OMIM 605018). CCS is transmitted in an autosomal dominant pattern, and has variable expressivity, both of the three syndromic phenotypes, and of the severity of tumour burden. Age-related penetrance figures are not precisely reported. The first tumours typically appear during puberty and progressively accumulate through adulthood. Penetrance is typically high, with equal numbers of males and females affected. Genetic testing is important for confirmation of the clinical diagnosis, genetic counselling and family planning, including preimplantation diagnosis. Additionally, identified CCS patients may be eligible for future clinical trials of non-surgical pre-emptive interventions that aim to prevent tumour growth. In this update, we review the clinical presentations of germline and mosaic CCS. An overview of the germline pathogenic variant spectrum of patients with CCS reveals more than 100 single nucleotide variants and small insertions and deletions in coding exons, most frequently resulting in predicted truncation. In addition, a minority of patients have large deletions involving the gene, intronic pathogenic variants that affect splicing, or inversions. We discuss germline and somatic testing approaches. Somatic testing of tumour tissue, relevant in mosaic CCS, can reveal recurrently detected pathogenic variants when two or more tumours are tested. This can influence genetic testing of children, who may inherit this as a germline variant, and inform genetic counselling and prenatal diagnosis. Finally, we discuss testing technologies that are currently used, their benefits and limitations, and future directions for genetic testing in CCS.
CYLD皮肤综合征(CCS)是遗传性皮肤附属器肿瘤综合征布鲁克-施皮格勒综合征(BSS - OMIM 605041)、家族性圆柱瘤病(FC - OMIM 132700)和多发性家族性毛发上皮瘤(MFT - OMIM 601606)的统称。这三种综合征均由肿瘤抑制基因CYLD(OMIM 605018)的种系致病变异引起。CCS以常染色体显性模式遗传,三种综合征型表型以及肿瘤负担的严重程度均具有可变表达性。与年龄相关的外显率数据尚无精确报道。首批肿瘤通常在青春期出现,并在成年期逐渐累积。外显率通常较高,男性和女性受影响的人数相等。基因检测对于临床诊断的确认、遗传咨询和计划生育(包括植入前诊断)非常重要。此外,确诊的CCS患者可能有资格参加旨在预防肿瘤生长的非手术预防性干预措施的未来临床试验。在本次更新中,我们回顾了种系和嵌合型CCS的临床表现。对CCS患者种系致病变异谱的概述显示,编码外显子中有100多个单核苷酸变异以及小的插入和缺失,最常见的结果是预测的截短。此外,少数患者存在涉及CYLD基因的大片段缺失、影响剪接的内含子致病变异或倒位。我们讨论了种系和体细胞检测方法。肿瘤组织的体细胞检测在嵌合型CCS中具有相关性,当检测两个或更多肿瘤时,可揭示反复检测到的致病变异。这可能会影响儿童的基因检测,因为他们可能会将此作为种系变异遗传下来,并为遗传咨询和产前诊断提供依据。最后,我们讨论了目前使用的检测技术、它们的优点和局限性以及CCS基因检测的未来方向。